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Highlights 
● The Evidence Investigator screens for a range of drugs in postmortem specimens 
● Qualitative results can be obtained in the time it takes to complete an autopsy 
● Assay results for each specimen was in good agreement with confirmatory analysis 
 
 
Abstract 
Background 
This paper describes the performance of four Randox drug arrays, designed for whole blood, 
for the near-body analysis of drugs in a range of post-mortem body specimens. 
Methods 
Liver, psoas muscle, femoral blood, vitreous humor and urine from 261 post-mortem cases 
were screened in the mortuary and results were obtained within the time taken to complete a 
post-mortem. Specimens were screened for the presence of amfetamine, barbiturates, 
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benzodiazepines, benzoylecgonine, buprenorphine, cannabinoids, dextropropoxyphene, 
fentanyl, ketamine, lysergide, methadone, metamfetamine, methaqualone, 3,4-
methylenedioxymetamfetamine, opioids, paracetamol, phencyclidine, salicylate, salicylic acid, 
zaleplon, zopiclone and zolpidem using the DOA I, DOA I+, DOA II and Custom arrays. 
Results 
Liver and muscle specimens were obtained from each of the 261 post-mortem cases; femoral 
blood, vitreous humor and urine were available in 98%, 92% and 72% of the cases, 
respectively. As such, the equivalent of 12,978 individual drug-specific, or drug-group, 
immunoassay tests were undertaken. Overall >98% of the 12,978 screening tests undertaken 
agreed with laboratory confirmatory tests performed on femoral blood. 
Conclusions 
There is growing interest in the development of non-invasive procedures for determining the 
cause of death using MRI and CT scanning however these procedures are, in most cases, 
unable to determine whether death may have been associated with drug use.  The Randox 
arrays can provide qualitative and semi-quantitative results in a mortuary environment 
enabling pathologists to decide whether to remove specimens from the body and submit them 
for laboratory analysis. Analysis can be undertaken on a range of autopsy specimens which 
is particularly useful when conventional specimens such as blood are unavailable. 
 
Keywords: Post-mortem, Toxicology, Near-body Drug Screening, Forensic Pathology, 
Laboratory Tests. 
  
Introduction 
Interest is increasing in the use of non-invasive techniques to ascertain the cause of death as 
a replacement for the traditional post-mortem examination. Magnetic resonance imaging 
(MRI) and computerised tomography (CT) scanning have been suggested in lieu of invasive 
post-mortems [1 – 3].  Whilst CT and MRI scanning may be suitable for the diagnosis of certain 
types of death there are weaknesses [3] and pathologists must still rely on the removal of 
AC
CE
PT
ED
 M
AN
US
CR
IPT
tissue specimens for laboratory analysis before drug or poisoning related deaths may be 
identified. The removal of post-mortem tissue can be complicated by legislation or religious 
custom hence a rapid near-body screen that can provide an indication of the presence of drugs 
in a body could be beneficial. Emergency departments, drug treatment clinics and workplace 
drug testing programs already use near-body drug screening to determine an individual’s 
recent drug use [4-9] but few reports describe the use of near-body methodologies for post-
mortem drug screening.  
Immunoassays are simple to use however the majority of drug screening immunoassays 
designed for clinical settings are not suitable for post-mortem cases as their cut-off limits are 
too high and drugs of forensic importance may be missed.  Furthermore, clinical near-patient 
tests are limited to detecting a small selection of common drugs of abuse and are also based 
on technology that requires relatively non-viscous specimens e.g. urine or oral fluid in order to 
operate. 
The Randox Evidence Investigator system relies on biochip technology rather than 
conventional lateral flow technology and is subsequently amenable for use with a wide range 
of tissue specimens. Each biochip measures 9 x 9 mm and can have up to 13 drug specific 
antibodies immobilised in predefined regions on the biochip. Chemiluminescence is employed 
to obtain semi-quantitative drug concentrations.  Light signals generated from each antibody 
site on the biochip are simultaneously detected using digital imaging technology and 
compared to that from a calibration curve. Nine biochips are mounted within individual wells 
on a single cassette enabling analysts to screen either nine different cases or fewer cases but 
a wider range of tissue specimens simultaneously. We previously reported on the performance 
of the Randox DOA I and DOA II panels in 106 forensic post-mortems [10].  In this paper we 
describe the use of the DOA I, DOA I+, DOA II and a “Custom Array” panel to detect a range 
of drugs (Table 1) in a variety of post-mortem toxicology specimens obtained from 261 post-
mortem cases. 
  
Table 1 Drugs detected using the DOA I, DOA I+, DOA II and Custom arrays 
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 DOA I  
(calibration range, 
LOD) 
DOA I+ 
(calibration range, 
LOD) 
DOA II 
(calibration 
range, LOD) 
Custom 
(calibration 
range, LOD) 
Amfetamine  
(0-108 ng/mL, 1.60 
ng/mL) 
Amfetamine  
(0-108 ng/mL, 1.60 
ng/mL) 
Buprenorphine 
(0-80 ng/ml, 
normalised 
value of 71) 
Paracetamol 
(0-695 µg/mL, 
1.045 µg/mL) 
Barbiturates  
(0-356 ng/mL, 1.59 
ng/mL) 
Barbiturates  
(0-356 ng/mL, 1.59 
ng/mL) 
Dextropropoxy
phene 
(0-2000 ng/ml, 
normalised 
value of 71) 
Salicylate 
(0 - 665 µg/ml, 
0.495 µg/mL) 
Benzodiazepines Ia 
(0-244 ng/mL, 0.37 
ng/mL) 
Benzodiazepines Ia  
(0-244 ng/mL, 0.37 
ng/mL) 
Fentanyl 
(0-40 ng/ml, 
normalised 
value of 76) 
Salicylic acid 
(0 - 665 µg/ml, 
0.495 µg/mL) 
Benzodiazepines IIa  
(0-280 ng/mL, 0.29 
ng/mL) 
Benzodiazepines IIa 
(0-280 ng/mL, 0.29 
ng/mL) 
Ketamine 
(0-2000 ng/ml, 
normalised 
value of 10) 
Zaleplon 
(0 - 202 ng/mL, 
0.1 ng/mL) 
Benzoylecgonine 
(0-244 ng/mL, 0.36 
ng/mL) 
Benzoylecgonine  
(0-244 ng/mL, 0.36 
ng/mL) 
Lysergide 
(0-8000 ng/ml, 
normalised 
value of 76) 
Zolpidem 
(0 – 137 ng/ml, 
0.075 ng/mL) 
Cannabinoids  
(0-40 ng/mL, 0.98 
ng/mL) 
Buprenorphine  
(0.08 ng/mL) 
Methaqualone 
(0-500 ng/ml, 
normalised 
value of 10) 
Zopiclone 
(0 - 516 ng/mL, 
0.375 ng/mL) 
Metamfetamine 
(0-368 ng/mL, 6.75 
ng/mL) 
Cannabinoids  
(0-40 ng/mL, 0.98 
ng/mL) 
3,4-
Methylenediox
ymetamfetami
ne 
(0-4000 ng/ml, 
normalised 
value of 77) 
  
Methadone  
(0-132 ng/mL, 0.16 
Metamfetamine Opioidsc 
(0-2000 ng/ml, 
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ng/mL) (0-368 ng/mL, 6.75 
ng/mL) 
normalised 
value of 53) 
Opiatesb  
(0-132 ng/mL, 0.09 
ng/mL) 
Methadone  
(0-132 ng/mL, 0.16 
ng/mL) 
Oxycodone Id 
(0-2000 ng/ml, 
normalised 
value of 43) 
  
Phencyclidine  
(0-48 ng/mL, 0.10 
ng/mL) 
3,4-
Methylenedioxymeta
mfetamine  
(1.93 ng/mL) 
Oxycodone IId 
(0-2000 ng/ml, 
normalised 
value of 18) 
  
  Opiatesb  
(0-132 ng/mL, 0.09 
ng/mL) 
    
  Phencyclidine  
(0-48 ng/mL, 0.10 
ng/mL) 
    
  Tricyclic 
Antidepressants  
(1.06 ng/mL) 
    
aBenzodiazepine I has high cross reactivity for oxazepam, midazolam, flunitrazepam, 
diazepam, temazepam, ethylflurazepam and clobazam whereas benzodiazepine II is specific 
for lorazepam. 
bOpiate antibody cross reacts with morphine (100%), 6-acetylmorphine (1214%), codeine 
(106%), morphine-3-glucuronide (16%) and hydromorphone (27%).  
cOpioid antibody cross reacts with hydrocodone (2282%), ethyl morphine (867%), 
hydromorphone (163%), codeine (291%), oxycodone (100%), dihydrocodeine (82%), 
thebaine (21%) and morphine (9%).    
dOxycodone I has higher cross reactivity for noroxycodone and hydrocodone compared to 
Oxycodone II. 
  
Materials and Methods 
Femoral blood, urine, vitreous humor, liver and psoas major muscle specimens were obtained 
from 261 consecutive forensic post-mortem cases carried out at the Sir James Black Mortuary, 
Dundee. Ethics permission was not necessary as the information obtained was included in the 
toxicology case report, following the guidelines by the Procurator Fiscal.  
Specimen Preparation 
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Blood was collected from the ligated femoral vein and urine was syringed from the bladder 
using a 10 mL syringe. Vitreous humor was collected with a 5 mL syringe and a 19 gauge 
needle via puncture through the sclera. Body fluids were collected into tubes containing 
sodium fluoride and potassium oxalate. The liver specimen was obtained from the right lobe 
and a 1 cm3 section of the psoas major muscle was also collected. On completion of screening 
all tissue specimens, other than blood, were returned to the body. 
Liver and psoas major muscle (1 cm3; approximate weight 1 g) were cut into small pieces and 
homogenised with 1 mL of the manufacturer’s diluent. Specimens were blended to form a 
smooth homogenate using a Janke Kunkel Ultra Turrax t25 homogeniser (IKA Laboratory).  
Homogenates were centrifuged for 10 minutes at 3000 rpm and 25 µL aliquots of the 
supernatant were removed. 25 µL aliquots of blood, vitreous humor, urine, and liver and 
muscle supernatant were diluted 1:3 v/v with assay diluent as per the kit manufacturer’s 
instruction. Specimens were thoroughly mixed using a vortex mixer prior to introduction of the 
specimen onto the biochip.   
  
Immunoassay Protocol 
A two day training course was provided by Randox to operate the Evidence Investigator 
system, the protocol was as follows. Assay diluent (120 µL) was added to each biochip 
followed by either 60 µL of a calibrator, control, or specimen. A calibration curve cassette and 
quality controls (low and high), provided by Randox, for each array were run alongside each 
set of case specimens. A conjugate (120 µL) consisting of horseradish peroxidase labelled 
analytes was added to compete for specific antibodies with any drug present in the specimen. 
Biochips were then incubated and agitated at 25°C for 30 minutes at 330 rpm in a 
‘Thermoshaker’. The DOA II array protocol differs from the DOA I, DOA I+ and Custom array 
only in that the DOA II array has an incubation temperature of 30°C and an increased agitation 
of 370 rpm. Subsequent to incubation each biochip was relieved of unbound analytes by 6 
quick washes followed by 6 two-minute soaks using the manufacturer’s wash buffer. Fluid 
remaining in the cassettes was drained onto absorbent paper. Luminol:peroxide signal reagent 
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(250 µL) was added to each biochip and the cassette was protected from light for 2 minutes 
prior to insertion into the Evidence Investigator imaging system for measurement of the 
chemiluminescence reaction.  
  
Confirmation 
Confirmatory analysis of the femoral blood specimens of all 261 cases was performed at the 
Centre of Forensic and Legal Medicine toxicology laboratory (Dundee) using LC-MS/MS, LC-
DAD and GC-MS. LC-MS/MS assay was performed using an AB Sciex 3200 Qtrap 
(Warrington, UK) with Agilent (Wokingham, UK) 1200 series HPLC system.  A Phenomenex 
Gemini column (150 mm x 2 mm) was used for analysis. A mobile phase of 3% acetonitrile for 
3 minutes increased to 65% acetonitrile over 20 minutes was used, total run time of 23 
minutes. Mobile phase A comprised 1 mM ammonium formate and 0.1% formic acid.  Mobile 
phase B comprised 70% acetonitrile, 1 mM ammonium formate and 0.1% formic acid.  
Detection by LC-DAD was based on a previously published method [11] using a Dionex 
(Camberley, UK) HPLC system fitted with a Phenomenex Synergi 4m Fusion 150 mm x 4.6 
mm column. Data acquisition was achieved using a diode array detector recording between 
200 nm and 595 nm. 
GC-MS was performed using an Agilent (Stockport, UK) 7890A gas chromatograph interfaced 
with an Agilent 5975C mass spectrometer using an adapted version of a previously published 
method [12]. The GC conditions involved splitless injection onto a HP-5MS column (30 m x 
0.25 mm ID, 0.25 µm film thickness); injection port temperature, 175°C; carrier gas, helium; 
flow rate, 1.7 ml/min; column temperature, 60°C for 1.5 min and increased by 10°C /min to 
220°C and held for an additional 9 min. The limit of detection (LOD) employed for barbiturates 
was 0.1 mg/L, tricyclic antidepressants, amine drugs and methadone 0.01 mg/L, and a LOD 
of 0.004 mg/L for opioids and benzodiazepines. 
 
Results 
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Blood, urine, vitreous humor, liver and muscle from 261 post-mortem cases were screened 
and results were obtained within 60 minutes of the pathologist providing the necessary 
specimens. Although the Evidence Investigator is reported to be semi-quantitative, the 
calibrators and controls were designed for whole blood. Therefore the assay results obtained 
for the biological specimens were only qualitative. Validation studies would have to be 
undertaken to determine the matrix effects to allow semi-quantitative data to be reported.  Liver 
and muscle specimens were obtained from all post-mortem cases whereas blood, vitreous 
humor and urine were available in 98%, 92% and 72% of the cases respectively. The post-
mortem cases were screened using the DOA I, DOA I+, DOA II, or the custom array, or a 
combination of two arrays. In total, 1,207 biochips across the four arrays were run that screen 
for several drugs, or drug classes, simultaneously (Table 1), equating to 12,978 individual 
drug/drug group screens being processed.   
 
Table 2 Summary of confirmed screening tests in different tissues compared against 
confirmed blood analysis 
  Liver Urine Muscle Blood Vitreous 
  Cases 
Confir
med 
% 
Agr
eed 
Cases 
Confir
med 
% 
Agr
eed 
Cases 
Confir
med 
% 
Agr
eed 
Cases 
Confir
med 
% 
Agr
eed 
Cases 
Confir
med 
% 
Agr
eed 
Amfetamin
e 
3 100 2 100 3 100 3 100 3 100 
Barbiturat
es 
1 100 1 100 1 100 1 100 1 100 
Benzodiaz
epines 
70 99 56 95 70 96 68 94 63 78 
Benzoylec
gonine 
1 100 1 100 1 100 1 100 1 100 
Methadon
e 
20 100 17 100 20 95 19 95 18 89 
Opiatesa 83 99 61 100 81 94 83 96 80 95 
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Opioidsa 15 100 10 100 15 100 15 87 13 100 
Oxycodon
ea 
2 100 2 100 2 100 2 100 2 100 
Paraceta
mol 
12 100 7 100 12 100 12 100 11 82 
Salicylate 11 100 10 100 11 100 11 91 11 91 
Tricyclic 
Antidepres
sants 
20 100 15 100 20 95 18 94 18 89 
Comparison of the number of cases in which confirmed screening test results (cases 
confirmed) are shown against the number of results confirmed in femoral blood (% agreed) for 
liver, urine, muscle, blood and vitreous humor. aOpiates, and opioids and oxycodone not 
grouped as different antibodies were used in the DOA I+ and DOA II arrays, respectively. 
 
Of the 261 post-mortem blood specimens that underwent confirmatory analyses, 151 were 
positive for one or more analytes.  The analytes detected by confirmatory analysis in the blood 
are listed in Table 2. Opiates and benzodiazepines were the most common groups of drugs 
detected whilst barbiturates and benzoylecgonine were only infrequently encountered. The 
liver screens were in ≥ 99% agreement with confirmatory analysis, urine ≥ 95%, muscle ≥ 
94%, blood ≥ 87% and vitreous humor ≥ 78%.  
 
Table 3 Kappa analysis between the Randox microchip screening test results in different 
tissues and the gas chromatography / mass spectrometry confirmatory analysis undertaken 
on whole blood specimens. 
  Liver Muscle Blood Vitreous 
Humor 
Urine 
Amfetamine .488 .316 .414 .854 .318 
Barbiturates .664 1.00 1.00 1.00 1.00 
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Benzodiazepines .945 .978 .932 .809 .956 
Benzoylecgonine 1.00 .956 1.00 1.00 1.00 
Methadone 1.00 .944 .970 .935 .967 
Opiatesa .888 .896 .958 .922 .820 
Opioidsa .871 .936 .870 .931 1.00 
Oxycodonea .783 1.00 1.00 1.00 .425 
Paracetamol .805 .684 .867 .842 .903 
Salicylate .801 .801 .784 .702 .676 
Tricyclic 
Antidepressants 
.885 .938 .901 .865 .859 
Statistical measurements using Kappa scores enables sets of data to be compared to observe 
agreement between the data sets.  Kappa scores between 0.81 -0.99 represent almost perfect 
agreement, 0.61-0.8 substantial agreement, 0.41-0.6 moderate agreement and 0.1 -0.2 slight 
agreement. aOpiates, and opioids and oxycodone not grouped as different antibodies were 
used in the DOA I+ and DOA II arrays, respectively. 
  
To take into account the possibility of chance agreement, Cohen’s Kappa testing [13] was 
undertaken. Kappa testing may be used to demonstrate the degree of agreement corrected 
for the element of chance agreement between the different screening tests and confirmatory 
analysis. Table 3 summarises the results of Kappa analysis between the Randox microchip 
screening test results in different biological specimens and confirmatory analysis undertaken 
on whole blood specimens.  
 
Table 4 Number of cases where non-concordant immunoassay results were obtained 
  Liver Muscle Blood Vitreous  Urine 
Amfetamine 6 12 8 1 8 
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Barbiturates 1 -  -  - -  
Benzodiazepines 4 1 2 1 -  
Metamfetamine 9 8 5 2 11 
Methadone - 1 - - 1 
3,4-
Methylenedioxymetamfetamin
e 
10 9 1 1 7 
Opiatesa 10 3 1 3 13 
Opioidsa 2 1 - 1 -  
Oxycodonea 1 - - - 4 
Paracetamol 3 5 2 - 1 
Salicylic acid 3 3 2 3 4 
Tricyclic antidepressants 4 1 2 2 4 
Total discrepancies (false 
positives) excluding THCb 
53 
  
44 
  
24 
  
14 
  
53 
  
Percentage of tests that 
disagreed with confirmatory 
analysis, false positives 
(excluding THCb) 
2.0% 1.7% 0.9% 0.6% 2.8% 
Percentage of tests that 
disagreed with confirmatory 
analysis, false positives and 
false negatives (excluding 
THCb) 
2.1% 2.0% 1.4% 1.6% 2.9% 
aOpiates, and opioids and oxycodone not grouped as different antibodies were used in the 
DOA I+ and DOA II arrays, respectively. bTHC Tetrahydrocannabinol - analyte that gives a 
positive indicator for cannabinoids.  
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Non-concordant immunoassay results were detected <3% of the post-mortem specimens 
(Table 4).   Liver and urine had the greatest occurrence of additional positives compared to 
their respective confirmed blood specimen, followed by muscle, blood and vitreous humor. 
False positive immunoassay results were detected in <1% of all blood specimens tested.  
 
In addition to the drugs listed in Table 2, cannabinoids were also detected using the DOA I and DOA 
I+ array. One or more tissue specimens obtained from 33 post-mortem cases gave positive cannabinoid 
screens, however confirmatory analysis for cannabinoids was not undertaken and therefore these results 
could not be included in Table 4.  
 
Although the test systems evaluated were reported to be capable of detecting buprenorphine, 
dextropropoxyphene, fentanyl, ketamine, lysergide, methaqualone, PCP, salicylic acid, 
zaleplon, zopiclone or zolpidem, no cases were encountered during the study period where 
these drugs were deemed present by the confirmatory methods. In addition, no false positives 
were obtained for the aforementioned drugs.  
  
Discussion 
Tissue selection for toxicological analysis during a post-mortem examination is dictated by 
availability and whilst analysis of peripheral blood specimens is the preferred option for 
interpretative purposes, alternative specimens are important in cases where blood may not be 
available. In putrefied bodies blood or urine may not be available and muscle may be less 
affected than liver or other tissues.  For interpretation peripheral blood is the desired specimen 
however, if no blood is obtainable liver is an excellent tissue for providing evidence of drug 
use as it is the major organ in the body where drugs are metabolised. Vitreous humor is 
particularly useful as a tissue for drug analysis in bodies subjected to major trauma although 
much has still to be learned concerning the relationship of drugs in this tissue to that in other 
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tissues.  In this study we therefore investigated the use of a microchip screening technique to 
observe how it would perform using a variety of different post-mortem tissues. 
The routine procedure employed at the Centre of Forensic and Legal Medicine (Dundee) was 
to perform confirmatory analysis on blood only.  In cases where blood is unavailable an 
alternative tissue is analysed.  Since only blood was used for confirmatory analysis, an 
assumption was made that where a positive screening result was observed in urine, vitreous 
humor, liver and muscle, the blood could be used to corroborate the screening result.  
Excellent correlation was observed between blood confirmation and liver and urine screening 
results (Table 2).  This is not surprising because liver is the principal organ responsible for 
drug metabolism and urine has a long drug detection window.  Muscle and blood also 
presented excellent overall agreement with the confirmatory results.  In the cases where 
positive correlation between screening and confirmatory analysis in blood and muscle was not 
observed it was noted that the blood drug concentrations were usually close to cut-off and 
patient case histories indicated infrequent or low drug consumption. Vitreous humor screening 
results were the most varied, agreement with confirmatory analyses ranged from 78-100%. 
However the Kappa analysis (Table 3) shows that there was almost perfect agreement 
between screening and confirmatory analysis for the majority of drugs, with amfetamine being 
the exception; scores between 0.81-0.99 represent almost perfect agreement, 0.61-0.8 
substantial agreement, 0.41-0.6 moderate agreement and 0.1-0.2 slight agreement [13].  
 
In general the additional drug positives (Table 4) could be supported by the individual’s case 
history with the exception of amine based drugs, and paracetamol and aspirin (indicated by 
salicylate, salicylic acid) as their use was not always recorded. The majority of non-concordant 
results were attributed to cross reaction between putrefactive amines and the amfetamine 
antibody. False positives for amfetamine, metamfetamine and 3,4-
methylenedioxymetamfetamine occurred in blood specimens from decedents who were left 
undiscovered for a number of weeks or were located in a warm environment. Urine, liver and 
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muscle were also adversely affected by putrefactants, as shown by GC/MS, however few false 
positive amfetamine, metamfetamine and 3,4-methylenedioxymetamfetamine results were 
obtained in vitreous humor specimens. In general fewer presumed false positives were 
detected in vitreous humor compared to blood, muscle, liver and urine (0.6% compared to 
0.9%, 1.7%, 2.0% and 2.8% respectively). This is most likely due to the isolated compartment 
in which vitreous humor is located and the selectivity of the tissue membrane. The selectivity 
of the vitreous membrane may also inhibit or delay the incorporation of some drugs into eye 
fluid could offer a possible explanation for the lower agreement of vitreous humor screening 
results with confirmation analysis. Cannabinoids were detected in 33 post-mortem cases and 
although no confirmatory analysis was undertaken to detect cannabinoids, good agreement 
was observed between screening results and the decedent’s case history where individuals 
were reported to be cannabis users. Cannabinoids were detected consistently in liver, muscle, 
blood and urine; however its presence was relatively infrequent in vitreous humor specimens. 
Only 2 out of 31 cases where vitreous humor was available gave positive screening tests for 
cannabinoids. In these 2 cases the blood, urine, liver and muscle specimens yielded high 
semi-quantitative concentrations (greater than the calibration range). This finding was also 
observed by Jenkins and O’Block [14] who reported positive cannabinoid vitreous humor 
results only when high concentrations were detected in the related blood specimen. 
  
Conclusion 
The Randox DOA I,  I+, II and Custom array drug screening panels offer pathologists and 
toxicologists the opportunity to screen a range of tissue specimens for the presence of 
common therapeutic and abused drugs, specifically those listed in Table 2. As many drugs on 
the four arrays were not detected by confirmatory analysis, comments cannot be made on 
their ability to detect true positives, however the lack of false positives can be commented 
upon. The screening procedure is simple, sufficiently sensitive to make it appropriate for use 
in forensic toxicology, and the speed with which the assay can be completed enables a drug 
screen to be undertaken whilst an autopsy is in progress. The assays may be used to screen 
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blood, urine, liver, vitreous humor and muscle enabling their use in cases where conventional 
specimens may be unavailable e.g. fire deaths or decomposed bodies. Excellent agreement 
for the presence of amfetamines, barbiturates, benzodiazepines, cocaine derivatives, 
methadone, opioids, paracetamol, salicylate and tricyclic antidepressants in liver, urine, blood 
and muscle were obtained between the near-body screening test and laboratory analysis of 
femoral blood specimens. Although confirmatory analysis for the presence of cannabinoids 
was not undertaken, the cases where cannabinoids were detected by the screening tests were 
corroborated by case histories. Vitreous fluid showed poorer correlation between the 
screening test and confirmatory analysis on blood however it is recognised that a number of 
factors can influence the passage of drugs into eye fluid.  
An indication of the presence or absence of drugs in a body whilst the post-mortem is being 
undertaken could influence the pathologist in deciding whether to remove organs for laboratory 
analysis, reducing the cost of death investigation and simplifying procedures associated with 
the Human Tissue Act. 
 
Acknowledgements 
The authors would like to thank Susan Cox for the data collection she undertook at Sir James 
Black Mortuary. This work was supported by Randox, supplying the instrument and reagents, 
and supporting the researcher’s travel and accommodation. 
 
Poppy McLaughlin conceptualisation, methodology, validation, formal analysis, investigation, 
writing -original draft and review & editing. 
Peter Maskell validation, investigation, writing -original draft and review & editing. 
Derrick Pounder conceptualisation, resources, writing -original draft and review & editing. 
David Osselton conceptualisation, methodology, writing -original draft and review & editing, 
supervision, funding acquisition. 
 
Acknowledgements 
The authors would like to thank Susan Cox for the data collection she undertook at Sir James 
Black Mortuary. This work was supported by Randox, supplying the instrument and reagents, 
and supporting the researcher’s travel and accommodation. 
  
AC
CE
PT
ED
MA
NU
SC
RI
PT
References 
  
[1] Rutty GN, Rutty JE. Perceptions of near virtual autopsies. J Forensic Leg Med 2011; 
18:306-9. 
  
[2] Rutty GN. Are autopsies necessary? The role of computed tomography as a possible 
alternative to invasive autopsies. Rechtsmedizine 2007; 17:21-8 
  
[3] Roberts ISD, Benamore RE, Benbow EW, Lee SH, Harris JN, Jackson A, et al. Post 
mortem imaging as an alternative autopsy in the diagnosis of adult deaths: a validation 
study. The Lancet 2012; 379:136-142. 
  
[4] Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. 
Mayo Clinic Proceedings 2008; 86:66-76. 
  
[5] Bush DM. The U.S. mandatory guidelines for federal workplace drug testing programs: 
current status and future considerations. Forensic Sci Int 2007; 174:111-9. 
  
[6] Manchikanti L, Malla Y, Wargo BW, Cash KA, Pampati V, Damron KS, et al. Protocol 
for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic 
pain patients: a prospective analysis of immunoassay and liquid chromatography tandem 
mass spectrometry (LC/MS/MS). Pain Physician 2010; 13:1-22. 
  
[7] Verstraete A, Peat M. Workplace Drug Testing. In: Moffat AC, Osselton MD, Widdop 
B, Watts J, editors. Clarke’s analysis of drugs and poisons. 4th ed. London: 
Pharmaceutical Press; 2011. p 73-86.  
  
[8] Attema-de Jonge ME, Peeters SYG, Franssen EJF. Performance of three point-of-care 
urinalysis test devices for drugs of abuse and therapeutic drugs applied in the emergency 
department. J Emerg Med 2012; 42:682-691. 
  
[9] Fernandez AA, Amigo N, Carbone MT, Mora A, Pinto M, Beltran J, Gasso S. Application 
of the Cozart DDS system to postmortem screening of drugs of abuse in vitreous humor. 
Forensic Toxicol 2009; 27:90-7. 
  
[10] McLaughlin PA, Pounder DJ, Maskell P, Osselton MD.  Real-time near-body drug 
screening during autopsy. 1: Use of the Randox biochip drugs of abuse DOA I and DOA II 
immunoassays. Forensic Toxicol 2013; 31:113-8. 
  
[11] Elliott SP, Hale KA. Applications of an HPLC-DAD drug screening system based on 
retention indices and UV spectra. J Anal Toxicol 1988; 22:280-290. 
  
[12] Gunn J, Kriger S, Terrell AR. Identification and quantitation of amphetamine, 
methamphetamine, MDMA, pseudoephedrine, and ephedrine in blood, plasma, and serum 
using gas chromatography-mass spectrometry (GC/MS). Clin Appl Mass Spectrom 2010; 
603:37-43. 
  
AC
CE
PT
ED
MA
NU
SC
RI
PT
[13] Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. 
Fam Med 2005. 37(5):360-363. 
  
[14] Jenkins AJ, Oblock J. Phencyclidine and cannabinoids in vitreous humor. Legal Med 
2008; 10:201-3. 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
